 Methods and apparatus for making liposomes |
| The present invention features methods and apparatus for producing liposomes. The methods and ... |
|
| Methods for fine particle formation |
| OF THE PREFERRED EMBODIMENTS A preferred embodiment of the present invention is shown in FIG. 1 ... |
|
| Methods and apparatus for making liposomes containing hydrophobic drugs |
| The present invention features methods and apparatus for producing liposomes containing hydrophobic ... |
|
| Incapacitating composition and a device for its use |
| I claim: 1. An incapacitating composition containing at least one active ingredient with an ... |
|
| Viral inactivation method using near critical, supercritical or critical fluids |
| The present invention will be described in detail as a method and apparatus for inactivating one ... |
|
| Dietary food supplement |
| The dietary food supplement embodying the invention includes a candy or sugar based confectionary ... |
|
| Composition for suppressing appetite |
| OF THE PREFERRED EMBODIMENTS The compositions of the invention comprise kavalactones and ... |
|
| Methods and materials for treating depression and mood disorder |
| Treatment of depression or mood disorder depends largely on a few central elements. Because mental ... |
|
| Methods and apparatus for fine particle formation |
| OF THE PREFERRED EMBODIMENTS A preferred embodiment of the present invention is shown in FIG. 1 ... |
|
| Sore throat spray |
| What is claimed is: 1. A throat spray for topical application to a sore throat, said throat spray ... |
|
|
Methods for treating hyperplasia
| Details |
|
Inventors: Cheng, Shu Jun; Wang, De Chang; Hara, Yukihiko; Lee, Insu P.; Ahn, Woong Shick;
Assignee: Cancer Instititute (Hospital), Chinese Academy of Medical Sciences (Beijing, CN); Mitsui Norin Co., Ltd. (Tokyo, JP)
Primary Examiner: Reamer; James H.
Assistant Examiner:
Attorney, Agent or Firm: Frishauf, Holtz, Goodman, Langer & Chick, P.C.
A method for a treatment of hyperplasia caused by papilloma virus, such as Condyloma acuminata, which comprises concomitantly topically and orally administering at least one tea catechin. Tea catechins do not involve the risk of side-effects and may be easily administered by the patients themselves. |
|
DETAILED DESCRIPTION OF THE INVENTION The tea catechins for use in the present invention are shown below in the following formula I ##STR1## wherein R.
sup.
1 represents H or OH and R.
sup.
2 represents H or ##STR2## The tea catechins are more specifically, epicatechin, epicatechin gallate, epigallocatechin gallate, gallocatechin, etc.
(including derivatives thereof).
These catechins can be used singly, or two or more may be mixed together.
Out of these it is particularly desirable to have (-)-epigallocatechin gallate as a main component.
Examples of tea catechin compositions for use in the present invention include the following: POLYPHENON 100.
TM.
(produced by Mitsui Norin Co.
; Composition: (+)-gallocatechin 1.
44 wt %, (-)-epicatechin 5.
81 wt %, (-)-epigallocatechin 17.
57 wt %, (-)-epicatechin gallate 12.
51 wt %, (-)-epigallocatechin gallate 53.
90 wt %; or POLYPHENON E.
TM.
(produced by Mitsui Norin Co.
; Composition: (-)-epicatechin 10.
8 wt %, (-)-epigallocatechin 9.
2 wt %, (-)-epicatechin gallate 6.
5 wt %, (-)-epigallocatechin gallate 54.
8 wt %, (-)-gallocatechin gallate 4.
0 wt %).
The formulations for the topical administration of the tea catechin compounds or tea catechin composition employed for the treatment of hyperplasia according to the present invention can be, for example, in the form of an ointment such as a cream, a jelly, or an emulsion; or in the form of a suppository such as a capsule, and usually the tea catechin component is combined with an excipient, an extending agent, an emulsifier, a dispersing agent, etc.
Vaseline is suitable as a base for the ointment.
For the ointment, the content of tea catechin should be between 2 to 20% by weight, preferably between 12 to 18% by weight, and more preferably 15% by weight.
In the case of a suppository, the content of tea catechin should be 50 to 500 mg/capsule, preferably 200 to 300 mg/capsule, or more preferably 250 mg/capsule.
A typical usage example for the ointment is to apply the ointment directly to the infected area of the external genital organs or vagina, a vaseline cream containing 2 to 20% by weight catechin, from once to several times everyday for a period of 1 to 2 months
|
|
Weight Loss and Supplements 
